Eyepoint Pharmaceuticals Report issue

For profit Phase 2 Phase 4
Founded: Watertown MA United States (1987)
Status: No NME R&D (1987)

Organization Overview

First Clinical Trial
2008
NCT00605423
First Marketed Drug
2018
dexamethasone
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Eye Point Pharmaceuticals | EyePoint Pharmaceuticals, Inc. | EYEPOINT PHARMS | pSivida Corp. | pSiVida Limited

Active Ingredients

Marketed Drugs (3)

Key: Eyepoint Pharmaceuticals (2) Acquired (1)

dexamethasone (2018)

fluocinolone acetonide (synalar) (2018)

urea (2018)

Drugs in Phase 4 Trials (3)

Key: Eyepoint Pharmaceuticals (2) Acquired (1)

dexamethasone (2 trials)

fluocinolone acetonide (synalar) (5 trials)

prednisolone (hydeltra) (1 trial)

Drugs in Phase 2 Trials (2)

aflibercept (zaltrap) (1 trial)

eyp-1901 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Macular Degeneration (Phase 2)

Panuveitis (Phase 3)

Pars Planitis (Phase 3)

Uveitis (Phase 3)

Uveitis, Intermediate (Phase 3)

Uveitis, Posterior (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 5